Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

@article{Brggemann2006ClinicalSO,
  title={Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.},
  author={Monika Br{\"u}ggemann and Thorsten Raff and Thomas Flohr and Nicola G{\"o}kbuget and Makoto Nakao and Joachim Dr. Droese and Silke L{\"u}schen and Christiane Pott and Matthias Ritgen and Urban J. Scheuring and Heinz A. Horst and Eckhard Thiel and Dieter Hoelzer and Claus Rainer Bartram and Michael Dr. Kneba},
  journal={Blood},
  year={2006},
  volume={107 3},
  pages={
          1116-23
        }
}
Adult patients with acute lymphoblastic leukemia (ALL) who are stratified into the standard-risk (SR) group due to the absence of adverse prognostic factors relapse in 40% to 55% of the cases. To identify complementary markers suitable for further treatment stratification in SR ALL, we evaluated the predictive value of minimal residual disease (MRD) and prospectively monitored MRD in 196 strictly defined SR ALL patients at up to 9 time points in the first year of treatment by quantitative… 

Figures and Tables from this paper

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials.

It is concluded that conversion to MRD positivity during the early postconsolidation phase in adult standard-risk ALL patients is highly predictive of subsequent hematologic relapse and salvage treatment in the ongoing GMALL trial is intended to be started at the time of recurrence of quantifiable MRD.

Status of minimal residual disease after induction predicts outcome in both standard and high‐risk Ph‐negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4‐2002 MRD Study

It is concluded that MRD evaluation after induction should be considered with conventional risk criteria for treatment decisions in adult ALL.

Minimal residual disease in acute lymphoblastic leukemia.

  • D. Campana
  • Medicine, Biology
    Seminars in hematology
  • 2009
The identification of new markers of leukemia and the use of increasingly refined assays should further facilitate routine monitoring of MRD and help to clarify the cellular and biologic features of leukemic cells that resist chemotherapy in vivo.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Day-29 marrow MRD was the most important prognostic variable in multi-variate analysis and associated with shorter event-free survival (EFS) in all risk groups; even patients with 0.1% day-29 MRD had poor outcome compared with patients negative for MRD patients.

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

MRD analysis during early postremission therapy improves risk definitions and bolsters risk-oriented strategies, and was the most significant risk factor for relapse.

Should Minimal Residual Disease Monitoring in Acute Lymphoblastic Leukemia be Standard of Care?

  • D. Campana
  • Medicine
    Current Hematologic Malignancy Reports
  • 2012
This article reviews MRD methodologies and clinical applications with emphasis on recently reported technical advances and prognostic associations, and the practical issues related to the implementation of MRD monitoring in the clinic.

The prognostic significance of minimal residual disease in adult Egyptian patients with precursor acute lymphoblastic leukemia.

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia

RFS, DoR, and OS are relatively short in patients with MRD-positive ALL, particularly at higher MRD levels, while alloHSCT may improve survival but has limitations.

Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia

The new development in standardized 8-color flow cytometry might well be able to compete with MRD-PCR methods and the more sensitive PCR techniques can be used also for identification of true low-risk patients with very low relapse rates, who might profit from treatment reduction.
...

References

SHOWING 1-10 OF 43 REFERENCES

Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.

After only 2 weeks of treatment, the authors were able to identify a patient population of 20% who may benefit from the least intensive treatment, defined by MRD levels 5 weeks after induction treatment and before consolidation.

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.

The association of MRD test results and DFS was independent of and greater than other standard predictors of outcome and is therefore important in determining treatment for individual patients.

Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.

Overall, MRD in adults in whom a translocation had not been identified was significantly higher than in comparably-treated children, suggesting that ALL in adults is more drug-resistant than in children.

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

Multivariate analysis showed that the immunologic evaluation of MRD at day +35 was the most relevant independent prognostic parameter for adult patients with ALL, and together with age, white blood cell count at diagnosis, and presence of the Philadelphia (Ph) chromosome, represented the most informative combination of variables for predicting relapse-free survival.

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

MRD detection by flow cytometry is a strong and independent outcome indicator in childhood ALL and standardization regarding absolute quantification on the basis of NCs and assessment during periods of continuous treatment promise to increase the accuracy, simplicity, and cost efficiency of the approach.

Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome.

Findings indicate that with the present treatment protocol MRD quantification at an early stage of therapy identifies patients with a very low risk of relapse and whether such patients with D29 MRD less than 0.01% can be cured with less intensive chemotherapy, which would reduce the risk of serious late effects as well as the costs of therapy.

Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.

Not only was the distribution of patients with T-ALL different over the MRD-based risk groups, the prognostic value of MRD levels at TP1 and TP2 was higher in T-alls than in precursor-B-ALL, and consistently higher RFS rates were found for MRd-negative T-all patients at the first 5 follow-up time points.

Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.

Overall the ability of positive and negative tests to predict relapse or CCR was weaker in this cohort of adult T-ALL patients than in T- and B-lineage childhood ALL and B -lineage adult ALL, which suggests that caution should be taken in using MRD data based on TCR gene rearrangements to predict prognosis in adults.